PURPOSE: To report radiological and pathological response to neo-adjuvant radiotherapy for extremity and trunk soft-tissue sarcomas. MATERIALS/ METHODS: Fifty patients were identified retrospectively. All patients had MRI imaging pre and post neo-adjuvant external beam radiotherapy. Tumor volumes were measured in 3D on T1 Gadolinium enhanced sequences. Pathological treatment response was quantified in terms of percentage of treatment-related necrosis for each case. RESULTS: Histopathologic responses to treatment varied from 0% to 100%. The median pathological treatment response was 67.5% for low-grade sarcomas and 50% for high-grade sarcomas. The median decrease in tumor volume was 13.8% for non-myxoid low-grade sarcomas, 82.1% for myxoid liposarcomas and <1% for high-grade sarcomas. A partial response on MRI (volume reduction ≥50%) was highly predictive of a good pathological response (p<0.001). Patients with stable disease on imaging or volumetric progression had wide ranging pathological responses. CONCLUSIONS: Soft-tissue sarcomas show significant pathological treatment responses in the form of hyaline fibrosis, necrosis and granulation tissue. Despite this, there is minimal early volumetric response to radiation, especially for high-grade tumors. Although radiological partial response was predictive of pathological response, the significance of radiological progression was unclear. Myxoid liposarcoma tumor type was predictive of both pathological and radiological tumor response.
PURPOSE: To report radiological and pathological response to neo-adjuvant radiotherapy for extremity and trunk soft-tissue sarcomas. MATERIALS/ METHODS: Fifty patients were identified retrospectively. All patients had MRI imaging pre and post neo-adjuvant external beam radiotherapy. Tumor volumes were measured in 3D on T1 Gadolinium enhanced sequences. Pathological treatment response was quantified in terms of percentage of treatment-related necrosis for each case. RESULTS: Histopathologic responses to treatment varied from 0% to 100%. The median pathological treatment response was 67.5% for low-grade sarcomas and 50% for high-grade sarcomas. The median decrease in tumor volume was 13.8% for non-myxoid low-grade sarcomas, 82.1% for myxoid liposarcomas and <1% for high-grade sarcomas. A partial response on MRI (volume reduction ≥50%) was highly predictive of a good pathological response (p<0.001). Patients with stable disease on imaging or volumetric progression had wide ranging pathological responses. CONCLUSIONS: Soft-tissue sarcomas show significant pathological treatment responses in the form of hyaline fibrosis, necrosis and granulation tissue. Despite this, there is minimal early volumetric response to radiation, especially for high-grade tumors. Although radiological partial response was predictive of pathological response, the significance of radiological progression was unclear. Myxoid liposarcoma tumor type was predictive of both pathological and radiological tumor response.
Authors: Nicholas Bhojwani; Peter Szpakowski; Sasan Partovi; Martin H Maurer; Ulrich Grosse; Hendrik von Tengg-Kobligk; Lisa Zipp-Partovi; Nathan Fergus; Christos Kosmas; Konstantin Nikolaou; Mark R Robbin Journal: Quant Imaging Med Surg Date: 2015-10
Authors: Jeremy R Wortman; Sree Harsha Tirumani; Harika Tirumani; Atul B Shinagare; Jyothi P Jagannathan; Jason L Hornick; Nikhil H Ramaiya Journal: Eur Radiol Date: 2015-08-28 Impact factor: 5.315
Authors: Donald E Thrall; Paolo Maccarini; Paul Stauffer; James Macfall; Marlene Hauck; Stacey Snyder; Beth Case; Keith Linder; Lan Lan; Linda McCall; Mark W Dewhirst Journal: Int J Hyperthermia Date: 2012 Impact factor: 3.914
Authors: Theodoros Soldatos; Shivani Ahlawat; Elizabeth Montgomery; Majid Chalian; Michael A Jacobs; Laura M Fayad Journal: Radiology Date: 2015-09-21 Impact factor: 11.105
Authors: Robert J Canter; Dariusz Borys; Abimbola Olusanya; Chin-Shang Li; Li-Yuan Lee; Robert D Boutin; Scott D Christensen; Robert M Tamurian; Arta M Monjazeb Journal: Ann Surg Oncol Date: 2014-02-20 Impact factor: 5.344
Authors: Wayne L Monsky; Bedro Jin; Chris Molloy; Robert J Canter; Chin Shang Li; Tzu C Lin; Daniel Borys; Walter Mack; Isaac Kim; Michael H Buonocore; Abhijit J Chaudhari Journal: Anticancer Res Date: 2012-11 Impact factor: 2.480